Feature | January 23, 2014

Researchers Use PET to Image Vulnerable Plaques Before Rupture

Team tests sugar-based tracer to find inflamed high-risk artery plaques

January 23, 2014 — An international research team at Icahn School of Medicine at Mount Sinai is testing a sugar-based tracer contrast agent to be used with positron emission tomography (PET) imaging to help identify dangerous inflammation and high-risk vulnerable atherosclerotic plaque inside vessel walls that causes acute heart attacks and strokes.
 
The team investigated possible advantages of the proposed imaging agent fluorodeoxymannose (FDM) sugar-based tracer in comparison to fluorodeoxyglucose (FDG), a glucose-based tracer widely used in patients undergoing PET imaging.
 
“Pre-clinical testing shows that PET imaging with the radiotracer FDM may potentially offer a more targeted strategy to detect dangerous, high-risk plaques and inflammation that may be associated with serious cardiovascular events,” said Jagat Narula, M.D., Ph.D., principal investigator, director of the cardiovascular imaging program at The Mount Sinai Hospital and associate dean of global health at Icahn. “Although the research team’s investigations of the FDM tracer shows that it performs comparably to the traditional FDG tracer, it is expected that the new sugar tracer may have an advantage to more specifically target inflammation because the plaque infiltrating macrophages develop mannose receptors (MRs).”
 
Co-author Jogeshwar Mukherjee, Ph.D., and his team of radiochemists at the University of California, Irvine, labeled FDM with Fluorine-18, which enters the cells through glucose transporters. Study results showed mannose is taken up by a specific subset of macrophage cells that dwell in high-risk plaques, which have developed the mannose receptors. This may represent the theoretical advantage of FDM over the FDG tracer. These macrophages (M2) within atherosclerotic plaques tend to overly express MRs, and are especially common in inflamed and hemorrhagic arterial lesions.
 
In the study FDG and FDM were compared using PET imaging in atherosclerosis animal models. Uptake of each tracer within atherosclerotic plaques and macrophage cells were similar and FDM tracers showed at least a 25 percent higher FDM uptake advantage due to MR-bearing macrophages.
 
“The FDM binds to MR-bearing macrophages while FDG does not bind to the MR receptors,” said study co-author Zahi Fayad, Ph.D., director of the Translational and Molecular Imaging Institute at Icahn.
 
Researchers also observed FDM uptake occurred in the presence of atherosclerosis and almost none in non-atherosclerosis control models.
 
For more information: www.mountsinai.org

Related Content

Artificial Intelligence Provides Faster, Clearer MRI Scans

A new artificial-intelligence-based approach to image reconstruction, called AUTOMAP, yields higher quality images from less data, reducing radiation doses for CT and PET and shortening scan times for MRI. Shown here are MR images reconstructed from the same data with conventional approaches, at left, and AUTOMAP, at right. Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital

News | Artificial Intelligence | July 17, 2018
A research team with funding from the National Institute for Biomedical Imaging and Bioengineering (NIBIB) has...
Researchers Trace Parkinson’s Damage in the Heart
News | PET Imaging | July 17, 2018
A new way to examine stress and inflammation in the heart will help Parkinson’s researchers test new therapies and...
Study Shows Biomarker Panel Boosts Lung Cancer Risk Assessment for Smokers
News | Lung Cancer | July 16, 2018
A four-protein biomarker blood test improves lung cancer risk assessment over existing guidelines that rely solely upon...
Siemens Healthineers Announces FDA Clearance of syngo.via VB30 Molecular Imaging Software
Technology | Nuclear Imaging | July 16, 2018
At the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), June 23-26 in Philadelphia...
Breast Cancer Follow-up Imaging Varies Widely
News | Breast Imaging | July 13, 2018
July 13, 2018 — Follow-up imaging for women...
Lack of Insurance Coverage Delaying Proton Therapy Clinical Trials
News | Proton Therapy | July 12, 2018
Randomized clinical trials are the gold standard of cancer research and can shed light on whether innovative, new...
Breast Cancer Studies Ignore Race, Socioeconomic Factors
News | Women's Health | July 11, 2018
A new commentary appearing in the July issue of Cancer Causes & Control points to evidence that social factors help...
High-Strength MRI May Release Mercury from Amalgam Dental Fillings
News | Magnetic Resonance Imaging (MRI) | July 05, 2018
Exposure to ultra-high-strength magnetic resonance imaging (MRI) may release toxic mercury from amalgam fillings in...
Researcher Investigates Eliminating Radiation for HER2-Positive Breast Cancer
News | Radiation Therapy | July 02, 2018
Researchers at The University of Kansas Cancer Center have launched a clinical trial that eliminates radiation from the...
Overlay Init